American Society of Hirudotherapy

Coagulation Factor XIIIa and Activated Protein C Activate Platelets via GPVI and PAR1

Research article published in International journal of molecular sciences (2022)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportGenomics & ProteomicsDe Simone I et al. · International journal of molecular sciences, 2022

Abstract

Platelet and coagulation activation are highly reciprocal processes driven by multi-molecular interactions. Activated platelets secrete several coagulation factors and expose phosphatidylserine, which supports the activation of coagulation factor proteins. On the other hand, the coagulation cascade generates known ligands for platelet receptors, such as thrombin and fibrin. Coagulation factor (F)Xa, (F)XIIIa and activated protein C (APC) can also bind to platelets, but the functional consequences are unclear. Here, we investigated the effects of the activated (anti)coagulation factors on platelets, other than thrombin. Multicolor flow cytometry and aggregation experiments revealed that the 'supernatant of (hirudin-treated) coagulated plasma' (SCP) enhanced CRP-XL-induced platelet responses, i.e., integrin αIIbβ3 activation, P-selectin exposure and aggregate formation. We demonstrated that FXIIIa in combination with APC enhanced platelet activation in solution, and separately immobilized FXIIIa and APC resulted in platelet spreading. Platelet activation by FXIIIa was inhibited by molecular blockade of glycoprotein VI (GPVI) or Syk kinase. In contrast, platelet spreading on immobilized APC was inhibited by PAR1 blockade. Immobilized, but not soluble, FXIIIa and APC also enhanced in vitro adhesion and aggregation under flow. In conclusion, in coagulation, factors other than thrombin or fibrin can induce platelet activation via GPVI and PAR receptors.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsBlood PlateletsFactor XIIIaFibrinHirudinsP-SelectinPhosphatidylserinesPlatelet ActivationPlatelet AggregationPlatelet Glycoprotein GPIIb-IIIa ComplexPlatelet Membrane GlycoproteinsProtein CReceptor, PAR-1Syk KinaseThrombin

Summary

Beyond thrombin, coagulation factor XIIIa and activated protein C activated platelets: FXIIIa acted through glycoprotein VI and Syk, immobilized APC caused PAR1-dependent platelet spreading, and immobilized, but not soluble, FXIIIa and APC enhanced adhesion and aggregation under flow.

Context

This in vitro study investigated whether coagulation factors other than thrombin—specifically Factor XIIIa and activated protein C (APC)—can activate platelets via GPVI and PAR1 receptors, using hirudin-treated coagulated plasma supernatant as part of the experimental preparation. Hirudin serves here purely as a laboratory anticoagulant reagent to remove thrombin's contribution, allowing isolation of other factors' platelet-activating effects. The findings deepen understanding of platelet–coagulation interplay, which is the very system leech anticoagulants like hirudin modulate. The article does not study hirudotherapy or the leech secretome; it simply employs hirudin as a tool.

Citation

Reference (Vancouver style)

De Simone I, Baaten CCFMJ, Jandrot-Perrus M, Gibbins JM, Ten Cate H, Heemskerk JWM, et al. Coagulation Factor XIIIa and Activated Protein C Activate Platelets via GPVI and PAR1. Int J Mol Sci. 2022;23(18):10203. doi:10.3390/ijms231810203. PMID: 36142125

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.